Group14 Technology
Rick Costantino has over 25 years of experience in the field of science and technology. Rick began their career in 1995 as a Scientist at Genentech. Three years later, they joined Alkermes Inc as a Senior Staff Scientist. In 2003, they were appointed as the Chief Scientific Officer of Delivery at Nastech Pharmaceutical (now MDRNA), where they developed and commercialized unique products to treat diseases and have the greatest impact on improving human health. In 2008, they founded Costantino Consulting. The following year, they took on the role of Vice President of R&D at enerG2 Technologies. In 2009, they were appointed as the Chief Scientific Officer at G2B Pharma Inc. Most recently, in 2016, they co-founded Group14 Technologies, where they serve as the CTO. Group14 enables the electrification of everything from tiny medical, consumer and commercial devices to every possible flavor and size of transportation.
Rick Costantino obtained their Bachelor of Science in Chemical Engineering from The Johns Hopkins University, followed by a Master of Science in Chemical Engineering from the same university. Rick then went on to complete their Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology in 1995.
This person is not in any teams
Group14 Technology
3 followers
The future is silicon. Anodes must improve and silicon has the most potential. Nano-scale silicon provides the best combination of capacity and power, but still not sufficient cycle life and nano-scale production approaches remain expensive. Group14 has applied deep materials research experience to develop a new, low-cost approach to nano-scale silicon production. Our nano-scale silicon has high purity, high capacity, good power, and good cycle life. We use its unique high performance carbon engineering abilities to create cohesive silicon-carbon nanocomposites that dramatically outperform traditional carbon coated silicons.